Braskem S.A. (BAK) Forms $28.28 Double Top; Last Week Vanda Pharmaceuticals Inc. (VNDA) Analysts

February 21, 2018 - By Jerrie Dane

Braskem S.A. (BAK) formed double top with $29.98 target or 6.00% above today’s $28.28 share price. Braskem S.A. (BAK) has $11.90 billion valuation. The stock increased 3.82% or $1.04 during the last trading session, reaching $28.28. About 490,758 shares traded or 13.95% up from the average. Braskem S.A. (NYSE:BAK) has risen 73.46% since February 21, 2017 and is uptrending. It has outperformed by 56.76% the S&P500.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Outperform” rating by Oppenheimer on Monday, October 30. The stock has “Buy” rating by Piper Jaffray on Tuesday, June 27. The company was maintained on Thursday, August 3 by Oppenheimer. Oppenheimer maintained it with “Buy” rating and $25.0 target in Sunday, November 12 report. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Thursday, August 3 with “Buy” rating. As per Wednesday, November 9, the company rating was initiated by Aegis Capital. Brean Capital initiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, October 21 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Monday, September 4 report. Jefferies maintained the shares of VNDA in report on Tuesday, February 13 with “Buy” rating. JMP Securities maintained it with “Market Outperform” rating and $18 target in Wednesday, March 9 report. See Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings:

13/02/2018 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $20 Initiates Coverage On
08/01/2018 Broker: Oppenheimer Rating: Buy Maintain
12/11/2017 Broker: Oppenheimer Rating: Buy New Target: $25.0 Maintain
30/10/2017 Broker: Oppenheimer Rating: Outperform Old Target: $21 New Target: $26 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain
04/09/2017 Broker: Jefferies Rating: Buy New Target: $21.0 Maintain
01/09/2017 Broker: JMP Securities Rating: Buy New Target: $24.0

Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.26, from 1.17 in 2017Q2. It increased, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,527 shares or 0% of its portfolio. Goldman Sachs Grp Inc stated it has 426,108 shares or 0% of all its holdings. Rhumbline Advisers has 51,321 shares. Us National Bank De reported 300 shares. Ameritas Invest Prns has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Tiaa Cref Inv Mgmt Llc holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 424,887 shares. Deutsche Savings Bank Ag, a Germany-based fund reported 203,817 shares. Macquarie Gru Limited owns 1.89 million shares for 0.06% of their portfolio. Birchview Capital L P owns 68,000 shares or 0.63% of their US portfolio. Aqr Ltd Liability reported 11,896 shares or 0% of all its holdings. Columbus Circle holds 0.02% or 57,310 shares in its portfolio. Quantitative Limited Company holds 0.03% or 146,200 shares. Highbridge Capital Mgmt Llc has invested 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Matarin Management Ltd invested in 38,075 shares. Parallax Volatility Advisers L P invested in 0% or 62,031 shares.

Since January 2, 2018, it had 0 buys, and 4 selling transactions for $3.36 million activity. Birznieks Gunther sold $130,777 worth of stock. Kelly James Patrick also sold $140,494 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday, January 2. Gulino Richard L. sold $157,565 worth of stock. Polymeropoulos Mihael Hristos sold $2.93M worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday, January 2.

The stock increased 1.17% or $0.2 during the last trading session, reaching $17.3. About 561,892 shares traded or 9.88% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since February 21, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $786.08 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.